Starling Oncology (STLN) closed at $6.29 on October 26, 2026, down 6.3% from the previous close, on volume of 1,781,286 shares (30-day average 1,286,402).
Data as of October 26, 2026.
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
Globe Newswire (Mon, 26-Oct 9:00 AM ET)
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Globe Newswire (Thu, 1-Oct 4:14 PM ET)
Starling Oncology to Participate in Wells Fargo Healthcare Conference
Globe Newswire (Mon, 24-Aug 9:00 AM ET)
Market Chameleon (Mon, 17-Aug 4:32 AM ET)
Globe Newswire (Mon, 17-Aug 8:00 AM ET)
STLN Ups Guidance for 2026 as Capitated Revenue Grows and Adjusted EBITDA Turns Positive
Market Chameleon (Fri, 7-Aug 3:06 AM ET)
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
Globe Newswire (Thu, 6-Aug 4:14 PM ET)
Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.
Starling Oncology trades on the NASDAQ stock market under the symbol STLN.
As of October 26, 2026, STLN stock price declined to $6.29 with 1,781,286 million shares trading.
STLN has a market cap of $628.89 million. This is considered a Small Cap stock.
Last quarter Starling Oncology reported $161 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.02.
The top ETF exchange traded funds that STLN belongs to (by Net Assets): VTI, IWM, VXF, IWO, FESM.
STLN support price is $6.47 and resistance is $6.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STLN shares will trade within this expected range on the day.
